Literature DB >> 32080887

Reciprocal Regulation Between Forkhead Box M1/NF-κB and Methionine Adenosyltransferase 1A Drives Liver Cancer.

Yuan Li1,2, Liqing Lu1,3, Jian Tu1,4, Jing Zhang1,5, Ting Xiong1,3, Wei Fan1, Jiaohong Wang1, Meng Li6, Yibu Chen6, Justin Steggerda7, Hui Peng1, Yongheng Chen3, Tony W H Li1, Zhi-Gang Zhou8, José M Mato9, Ekihiro Seki1, Ting Liu2,3, Heping Yang1, Shelly C Lu1.   

Abstract

BACKGROUND AND AIMS: Forkhead box M1 (FOXM1) and nuclear factor kappa B (NF-ĸB) are oncogenic drivers in liver cancer that positively regulate each other. We showed that methionine adenosyltransferase 1A (MAT1A) is a tumor suppressor in the liver and inhibits NF-ĸB activity. Here, we examined the interplay between FOXM1/NF-κB and MAT1A in liver cancer. APPROACH AND
RESULTS: We examined gene and protein expression, effects on promoter activities and binding of proteins to promoter regions, as well as effects of FOXM1 inhibitors T0901317 (T0) and forkhead domain inhibitory-6 (FDI-6) in vitro and in xenograft and syngeneic models of liver cancer. We found, in both hepatocellular carcinoma and cholangiocarcinoma, that an induction in FOXM1 and NF-κB expression is accompanied by a fall in MATα1 (protein encoded by MAT1A). The Cancer Genome Atlas data set confirmed the inverse correlation between FOXM1 and MAT1A. Interestingly, FOXM1 directly interacts with MATα1 and they negatively regulate each other. In contrast, FOXM1 positively regulates p50 and p65 expression through MATα1, given that the effect is lost in its absence. FOXM1, MATα1, and NF-κB all bind to the FOX binding sites in the FOXM1 and MAT1A promoters. However, binding of FOXM1 and NF-κB repressed MAT1A promoter activity, but activated the FOXM1 promoter. In contrast, binding of MATα1 repressed the FOXM1 promoter. MATα1 also binds and represses the NF-κB element in the presence of p65 or p50. Inhibiting FOXM1 with either T0 or FDI-6 inhibited liver cancer cell growth in vitro and in vivo. However, inhibiting FOXM1 had minimal effects in liver cancer cells that do not express MAT1A.
CONCLUSIONS: We have found a crosstalk between FOXM1/NF-κB and MAT1A. Up-regulation in FOXM1 lowers MAT1A, but raises NF-κB, expression, and this is a feed-forward loop that enhances tumorigenesis.
© 2020 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32080887      PMCID: PMC7442711          DOI: 10.1002/hep.31196

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  36 in total

Review 1.  NF-κB and STAT3 - key players in liver inflammation and cancer.

Authors:  Guobin He; Michael Karin
Journal:  Cell Res       Date:  2010-12-28       Impact factor: 25.617

2.  The NF-κB genomic landscape in lymphoblastoid B cells.

Authors:  Bo Zhao; Luis A Barrera; Ina Ersing; Bradford Willox; Stefanie C S Schmidt; Hannah Greenfeld; Hufeng Zhou; Sarah B Mollo; Tommy T Shi; Kaoru Takasaki; Sizun Jiang; Ellen Cahir-McFarland; Manolis Kellis; Martha L Bulyk; Elliott Kieff; Benjamin E Gewurz
Journal:  Cell Rep       Date:  2014-08-21       Impact factor: 9.423

3.  Prohibitin 1 suppresses liver cancer tumorigenesis in mice and human hepatocellular and cholangiocarcinoma cells.

Authors:  Wei Fan; Heping Yang; Ting Liu; Jiaohong Wang; Tony W H Li; Nirmala Mavila; Yuanyuan Tang; JinWon Yang; Hui Peng; Jian Tu; Alagappan Annamalai; Mazen Noureddin; Anuradha Krishnan; Gregory J Gores; Maria L Martínez-Chantar; José M Mato; Shelly C Lu
Journal:  Hepatology       Date:  2017-01-31       Impact factor: 17.425

4.  Activation of LKB1-Akt pathway independent of phosphoinositide 3-kinase plays a critical role in the proliferation of hepatocellular carcinoma from nonalcoholic steatohepatitis.

Authors:  Nuria Martínez-López; Marta Varela-Rey; David Fernández-Ramos; Ashwin Woodhoo; Mercedes Vázquez-Chantada; Nieves Embade; Luis Espinosa-Hevia; Francisco Javier Bustamante; Luis A Parada; Manuel S Rodriguez; Shelly C Lu; José M Mato; Maria L Martínez-Chantar
Journal:  Hepatology       Date:  2010-11       Impact factor: 17.425

Review 5.  FOXM1: From cancer initiation to progression and treatment.

Authors:  Chuay-Yeng Koo; Kyle W Muir; Eric W-F Lam
Journal:  Biochim Biophys Acta       Date:  2011-09-29

6.  The prognostic landscape of genes and infiltrating immune cells across human cancers.

Authors:  Andrew J Gentles; Aaron M Newman; Chih Long Liu; Scott V Bratman; Weiguo Feng; Dongkyoon Kim; Viswam S Nair; Yue Xu; Amanda Khuong; Chuong D Hoang; Maximilian Diehn; Robert B West; Sylvia K Plevritis; Ash A Alizadeh
Journal:  Nat Med       Date:  2015-07-20       Impact factor: 53.440

7.  Foxm1 transcription factor is required for the initiation of lung tumorigenesis by oncogenic Kras(G12D.).

Authors:  I-C Wang; V Ustiyan; Y Zhang; Y Cai; T V Kalin; V V Kalinichenko
Journal:  Oncogene       Date:  2013-11-11       Impact factor: 9.867

8.  LXRα-mediated downregulation of FOXM1 suppresses the proliferation of hepatocellular carcinoma cells.

Authors:  C Hu; D Liu; Y Zhang; G Lou; G Huang; B Chen; X Shen; M Gao; W Gong; P Zhou; S Dai; Y Zeng; F He
Journal:  Oncogene       Date:  2013-07-01       Impact factor: 9.867

9.  Expression pattern, regulation, and functions of methionine adenosyltransferase 2beta splicing variants in hepatoma cells.

Authors:  Heping Yang; Ainhoa Iglesias Ara; Nathaniel Magilnick; Meng Xia; Komal Ramani; Hui Chen; Taunia D Lee; José M Mato; Shelly C Lu
Journal:  Gastroenterology       Date:  2007-10-18       Impact factor: 22.682

10.  The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data.

Authors:  Ethan Cerami; Jianjiong Gao; Ugur Dogrusoz; Benjamin E Gross; Selcuk Onur Sumer; Bülent Arman Aksoy; Anders Jacobsen; Caitlin J Byrne; Michael L Heuer; Erik Larsson; Yevgeniy Antipin; Boris Reva; Arthur P Goldberg; Chris Sander; Nikolaus Schultz
Journal:  Cancer Discov       Date:  2012-05       Impact factor: 39.397

View more
  11 in total

1.  S-adenosylmethionine inhibits la ribonucleoprotein domain family member 1 in murine liver and human liver cancer cells.

Authors:  Komal Ramani; Aaron E Robinson; Joshua Berlind; Wei Fan; Aushinie Abeynayake; Aleksandra Binek; Lucía Barbier-Torres; Mazen Noureddin; Nicholas N Nissen; Zehra Yildirim; Ebru Erbay; José M Mato; Jennifer E Van Eyk; Shelly C Lu
Journal:  Hepatology       Date:  2021-12-18       Impact factor: 17.425

2.  Programming to S1PR1+ Endothelial Cells Promotes Restoration of Vascular Integrity.

Authors:  Md Zahid Akhter; Jagdish Chandra Joshi; Vijay Avin Balaji Ragunathrao; Mark Maienschein-Cline; Richard L Proia; Asrar B Malik; Dolly Mehta
Journal:  Circ Res       Date:  2021-04-30       Impact factor: 23.213

Review 3.  Methionine metabolism in chronic liver diseases: an update on molecular mechanism and therapeutic implication.

Authors:  Zhanghao Li; Feixia Wang; Baoyu Liang; Ying Su; Sumin Sun; Siwei Xia; Jiangjuan Shao; Zili Zhang; Min Hong; Feng Zhang; Shizhong Zheng
Journal:  Signal Transduct Target Ther       Date:  2020-12-04

4.  Mining of RNA Methylation-Related Genes and Elucidation of Their Molecular Biology in Gallbladder Carcinoma.

Authors:  Changhong Yang; Jialei Chen; Zhe Yu; Jing Luo; Xuemei Li; Baoyong Zhou; Ning Jiang
Journal:  Front Oncol       Date:  2021-02-25       Impact factor: 6.244

5.  Forkhead Domain Inhibitor-6 Suppresses Corneal Neovascularization and Subsequent Fibrosis After Alkali Burn in Rats.

Authors:  Chunlin Lan; Guo Liu; Longxiang Huang; Xizhen Wang; Junkai Tan; Yun Wang; Ning Fan; Yihua Zhu; Man Yu; Xuyang Liu
Journal:  Invest Ophthalmol Vis Sci       Date:  2022-04-01       Impact factor: 4.925

6.  MELK predicts poor prognosis and promotes metastasis in esophageal squamous cell carcinoma via activating the NF‑κB pathway.

Authors:  Jiecheng Ye; Wanying Deng; Ying Zhong; Hui Liu; Baoyin Guo; Zixi Qin; Peiwen Li; Xueyun Zhong; Lihui Wang
Journal:  Int J Oncol       Date:  2022-06-22       Impact factor: 5.884

7.  Comprehensive analysis for cellular senescence-related immunogenic characteristics and immunotherapy prediction of acute myeloid leukemia.

Authors:  Yan Mao; Jinwen Xu; Xuejiao Xu; Jiayun Qiu; Zhengyun Hu; Feng Jiang; Guoping Zhou
Journal:  Front Pharmacol       Date:  2022-09-26       Impact factor: 5.988

Review 8.  Interplay between nuclear factor erythroid 2-related factor 2 and inflammatory mediators in COVID-19-related liver injury.

Authors:  Dan-Dan Zhu; Xue-Mei Tan; Li-Qing Lu; Si-Jia Yu; Ru-Li Jian; Xin-Fang Liang; Yi-Xuan Liao; Wei Fan; Lucíia Barbier-Torres; Austin Yang; He-Ping Yang; Ting Liu
Journal:  World J Gastroenterol       Date:  2021-06-14       Impact factor: 5.742

Review 9.  Omics-Based Platforms: Current Status and Potential Use for Cholangiocarcinoma.

Authors:  Yu-Chan Chang; Ming-Huang Chen; Chun-Nan Yeh; Michael Hsiao
Journal:  Biomolecules       Date:  2020-09-28

10.  Inhibition of microRNA-128-3p alleviates liver ischaemia-reperfusion injury in mice through repressing the Rnd3/NF-κB axis.

Authors:  Tong Mou; Yunhai Luo; Zuotian Huang; Daofeng Zheng; Xingyu Pu; Ai Shen; Junliang Pu; Tingting Li; Jiangwen Dai; Wei Chen; Zhongjun Wu
Journal:  Innate Immun       Date:  2020-06-02       Impact factor: 2.680

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.